Detalhe da pesquisa
1.
Survival with Cemiplimab in Recurrent Cervical Cancer.
N Engl J Med
; 386(6): 544-555, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35139273
2.
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
N Engl J Med
; 385(20): 1856-1867, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34534429
3.
A systematic review of stage IVA cervical cancer treatment: Challenges in the management of an understudied group.
Gynecol Oncol
; 187: 120-127, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38759518
4.
A review of racial disparities in ovarian cancer and clinical trials.
Curr Opin Obstet Gynecol
; 36(1): 23-27, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38170549
5.
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 24(4): 392-402, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36878237
6.
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.
Gynecol Oncol
; 171: 141-150, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36898292
7.
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Gynecol Oncol
; 170: 300-308, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36758420
8.
The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
Gynecol Oncol
; 173: 130-137, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37148580
9.
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
Gynecol Oncol
; 174: 213-223, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37229879
10.
Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey.
Cancer Control
; 30: 10732748231182795, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646470
11.
Sentinel lymphatic mapping for gynecologic malignancies.
Curr Opin Obstet Gynecol
; 35(1): 43-53, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36595648
12.
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer.
N Engl J Med
; 380(24): 2317-2326, 2019 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31189035
13.
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
N Engl J Med
; 381(20): 1929-1939, 2019 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31722153
14.
The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.
Gynecol Oncol
; 167(3): 429-435, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36244828
15.
Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.
Gynecol Oncol
; 164(2): 428-436, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34903380
16.
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Gynecol Oncol
; 164(2): 278-287, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34930617
17.
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
Gynecol Oncol
; 164(2): 398-405, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34857397
18.
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer.
Gynecol Oncol
; 166(3): 410-416, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35835612
19.
Risk factors for cervical cancer among distinct populations in low-resource countries: feasibility of cervical cancer screen-and-treat program on ukerewe island of lake victoria, Tanzania.
Curr Opin Obstet Gynecol
; 34(1): 20-27, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34967811
20.
Current and emerging immunotherapies for recurrent cervical cancer.
Clin Adv Hematol Oncol
; 20(2): 108-115, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35120091